Meys, Roy http://orcid.org/0000-0002-4855-530X
Stoffels, Anouk A. F.
Houben-Wilke, Sarah
Janssen, Daisy J. A.
Burtin, Chris
van Hees, Hieronymus W. H.
Franssen, Frits M. E.
van den Borst, Bram
Wouters, Emiel F. M.
Spruit, Martijn A.
,
Funding for this research was provided by:
Longfonds (5.1.18.232, 3.4.10.015)
GlaxoSmithKline (SCO115406)
Article History
Received: 17 September 2019
Accepted: 22 July 2020
First Online: 5 September 2020
Ethics approval and consent to participate
: The COPD, health status and co-morbidities (Chance) study was approved by the local ethics committee of Maastricht University Medical Centre+, The Netherlands (MEC 11–3-070). All patients gave written informed consent.
: Not applicable.
: DJAJ reports personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from Astra Zeneca, <i>outside the submitted work</i>; FMEF reports grants and personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from GlaxoSmithKline, grants and personal fees from Novartis, personal fees from TEVA, <i>outside the submitted work</i>; BB reports personal fees from AstraZeneca, personal fees from Boehringer Ingelheim bv, <i>outside the submitted work</i>; EFMW reports personal fees from Nycomed, personal fees from Boehringer Ingelheim BV, grants and personal fees from AstraZeneca, grants and personal fees from GlaxoSmithKline, personal fees from Novartis, personal fees from Chiesi, <i>outside the submitted work</i>; MAS reports grants from Lung Foundation Netherlands, grants from GlaxoSmithKline Netherlands, <i>during the conduct of the study</i>. RM, AAFS, SH-W, CB and HWHH have nothing to disclose.